Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOTRICITY INC.BTCY · Entity 8507 | Director | March 12, 2023 | March 15, 2023 |
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | Director | February 14, 2025 | February 19, 2025 |
| Healthcare Triangle, Inc.HCTI · Entity 7909 | Director | March 12, 2024 | March 13, 2024 |
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | Director · CEO & President | August 28, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOTRICITY INC.
Report date March 12, 2023 · Filed March 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.94 · Expires 2028-03-12 | Direct | 474,683 |
Reported balance
After 2023-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-12 · Grant · Acquired 75,930 · Balance 474,683 F1: Granted pursuant to the 2016 Equity Incentive Plan; with immediate vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the 2016 Equity Incentive Plan; with immediate vesting.
BioRestorative Therapies, Inc.
Report date February 14, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2035-02-14 | Direct | 52,632 |
Reported balance
After 2025-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-14 · Grant · Acquired 52,632 · Balance 52,632 F2: The option vests and becomes exercisable in twelve nearly equal monthly installments of 4,386 shares beginning on March 14, 2025 and continuing every month thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-11-04 | Direct | 10,490 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 10,490 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2033-02-17 | Direct | 32,028 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 32,028 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2034-02-13 | Direct | 79,646 |
Reported balance
Holding disclosure · report date 2025-02-14 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 79,646 F1: The option is currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is currently exercisable.
F2: The option vests and becomes exercisable in twelve nearly equal monthly installments of 4,386 shares beginning on March 14, 2025 and continuing every month thereafter until fully vested.
Healthcare Triangle, Inc.
Report date March 12, 2024 · Filed March 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.78 · Expires 2029-03-12 | Direct | 34,000 |
Reported balance
After 2024-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-12 · Grant · Acquired 10,000 · Balance 34,000 F2: Incentive stock option granted 03/12/2024 under the Company's 2020 Stock Incentive Plan. All options expire within a 5-year period, with all 10,000 options vesting immediately. F1: On May 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split.
F2: Incentive stock option granted 03/12/2024 under the Company's 2020 Stock Incentive Plan. All options expire within a 5-year period, with all 10,000 options vesting immediately.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date August 28, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2036-08-27 | Direct | 68,000 |
Reported balance
After 2026-08-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-28 · Grant · Acquired 68,000 · Balance 68,000 F1: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Aug 28, 2026 20:51 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 68,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001540354-26-000006 · primary_doc.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2036-08-27 F1 · derivative.exercise_date: 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 20:01 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,458 | $0.78 | $1,909.87 |
DisclosureSEC source: 0001540354-26-000005 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,080,132 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 19:15 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 71,325 | $0.68 | $48,501.00 |
DisclosureSEC source: 0001540354-26-000004 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,082,590 Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:38 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,458 | $0.76 | $1,863.16 |
DisclosureSEC source: 0001540354-26-000001 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,153,915 Read SEC document |
| September 30, 2025 Filed Oct 1, 2025 18:05 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,458 | $0.89 | $2,184.18 |
DisclosureSEC source: 0001540354-25-000009 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,156,373 Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 14:42 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,458 | $0.68 | $1,666.52 |
DisclosureSEC source: 0001540354-25-000006 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,158,831 Read SEC document |
| April 17, 2025 Filed Apr 21, 2025 20:34 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 750,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001540354-25-000005 · primary_doc.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2035-04-16 F1 · derivative.exercise_date: 25% will vest on April 17, 2026, and the remaining 75% will vest in 12 equal quarterly installments. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 20:38 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | PurchaseCommon Stock | 100,000 | $0.50 | $50,000.00 |
DisclosureSEC source: 0001540354-25-000004 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,161,289 Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 19:56 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,458 | $0.85 | $2,089.79 |
DisclosureSEC source: 0001540354-25-000003 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,061,289 Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:05 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 71,325 | $1.16 | $82,737.00 |
DisclosureSEC source: 0001540354-25-000002 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,063,747 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 52,632 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001021771-25-000046 · form4.xml · derivative · entry 4 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,632 Underlying: Common Stock · 52,632 shares Expires 2035-02-14 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve nearly equal monthly installments of 4,386 shares beginning on March 14, 2025 and continuing every month thereafter until fully vested. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:33 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.15 | $2,574.85 |
DisclosureSEC source: 0001540354-25-000001 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,135,072 Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 20:39 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 4,697 | $0.83 | $3,879.72 |
DisclosureSEC source: 0001213900-25-000714 · ownership.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,137,311 Read SEC document |
| November 30, 2024 Filed Dec 3, 2024 21:50 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $0.62 | $1,395.12 |
DisclosureSEC source: 0001540354-24-000013 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,142,008 Read SEC document |
| October 31, 2024 Filed Nov 1, 2024 21:06 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $0.97 | $2,171.83 |
DisclosureSEC source: 0001540354-24-000012 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,144,247 Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 15:22 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 4,697 | $0.99 | $4,650.03 |
DisclosureSEC source: 0001540354-24-000011 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,146,486 Read SEC document |
| August 31, 2024 Filed Sep 4, 2024 15:26 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $0.80 | $1,783.14 |
DisclosureSEC source: 0001540354-24-000010 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,151,183 Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 18:16 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $0.75 | $1,679.25 |
DisclosureSEC source: 0001540354-24-000009 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,153,422 Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 15:09 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 4,697 | $0.80 | $3,757.60 |
DisclosureSEC source: 0001540354-24-000008 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,155,661 Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 15:24 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $0.93 | $2,082.05 |
DisclosureSEC source: 0001540354-24-000007 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,160,358 Read SEC document |
| April 30, 2024 Filed May 2, 2024 12:49 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.13 | $2,530.07 |
DisclosureSEC source: 0001540354-24-000006 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,162,597 Read SEC document |
| April 21, 2024 Filed Apr 23, 2024 13:53 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 19,673 | $1.15 | $22,623.95 |
DisclosureSEC source: 0001540354-24-000005 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,164,836 Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 15:34 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.20 | $2,686.80 |
DisclosureSEC source: 0001540354-24-000004 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,184,509 Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 17:00 UTC | Healthcare Triangle, Inc. HCTI · Entity 7909 | GrantIncentive Stock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-24-022216 · ownership.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 10,000 shares Expires 2029-03-12 F2 · derivative.underlying_shares: Incentive stock option granted 03/12/2024 under the Company's 2020 Stock Incentive Plan. All options expire within a 5-year period, with all 10,000 options vesting immediately. F1 · balance_after: On May 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Split"). Unless otherwise noted, the amount of securities and purchase prices reported on this Form 4 have been adjusted to reflect the Reverse Split. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 19:01 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.21 | $2,709.19 |
DisclosureSEC source: 0001540354-24-000003 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,186,748 Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 15:14 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 663,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001540354-24-000002 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,188,987 F1 · shares: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 79,646 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001021771-24-000056 · form4.xml · derivative · entry 3 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,646 Underlying: Common Stock · 79,646 shares Expires 2034-02-13 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve nearly equal monthly installments of 6,637 shares beginning on March 13, 2024 and continuing every month thereafter until fully vested. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 18:29 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.25 | $2,798.75 |
DisclosureSEC source: 0001540354-24-000001 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,490 Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 18:29 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.58 | $3,537.62 |
DisclosureSEC source: 0001213900-24-000530 · ownership.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,729 Read SEC document |
| November 30, 2023 Filed Dec 4, 2023 21:09 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.45 | $3,246.55 |
DisclosureSEC source: 0001540354-23-000013 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 529,968 Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 22:30 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 526,303 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001540354-23-000012 · primary_doc.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526,303 Underlying: Common Stock · 526,303 shares Expires 2033-11-08 F1 · derivative.exercise_date: 25% will vest on November 9, 2024, and the remaining 75% will vest in 36 equal monthly installments on the last day of each month following November 9, 2024. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 19:50 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.61 | $3,604.79 |
DisclosureSEC source: 0001540354-23-000011 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 532,207 Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 19:56 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $0.90 | $2,015.10 |
DisclosureSEC source: 0001540354-23-000010 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,446 Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 19:21 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $0.89 | $1,993.61 |
DisclosureSEC source: 0001540354-23-000009 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,685 Read SEC document |
| August 31, 2023 Filed Sep 5, 2023 15:25 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $0.85 | $1,904.27 |
DisclosureSEC source: 0001540354-23-000008 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 538,924 Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 19:35 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.02 | $2,283.78 |
DisclosureSEC source: 0001540354-23-000007 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 541,163 Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 17:49 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.20 | $2,686.80 |
DisclosureSEC source: 0001540354-23-000006 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 543,402 Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 20:36 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.21 | $2,709.19 |
DisclosureSEC source: 0001540354-23-000005 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,641 Read SEC document |
| April 30, 2023 Filed May 2, 2023 19:29 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.54 | $3,448.06 |
DisclosureSEC source: 0001540354-23-000004 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 547,880 Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 18:58 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 91,500 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001540354-23-000003 · primary_doc.xml · derivative · entry 2 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,500 Underlying: Common Stock · 91,500 shares Expires 2033-04-20 F2 · derivative.exercise_date: 25% will vest on April 21, 2024 and the remaining 75% will vest in 12 equal quarterly installments on the last day of each quarter beginning on June 30, 2024. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 18:58 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 91,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001540354-23-000003 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,119 F1 · shares: Represents a grant of restricted stock units, which vest as to 50% of the shares on the first anniversary of the grant date, with the remaining shares vesting in equal quarterly installments on the last day of each quarter over the next 8 quarters, subject to continued service on such vesting date. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:12 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 2,239 | $1.61 | $3,604.79 |
DisclosureSEC source: 0001540354-23-000002 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 458,619 Read SEC document |
| March 12, 2023 Filed Mar 15, 2023 20:22 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantOption (right to buy) · Derivative | 75,930 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001493152-23-007760 · ownership.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474,683 Underlying: Common Stock · 75,930 shares Expires 2028-03-12 F1 · derivative.exercise_date: Granted pursuant to the 2016 Equity Incentive Plan; with immediate vesting. Read SEC document |
| February 17, 2023 Filed Feb 17, 2023 22:38 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 32,028 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001567619-23-003334 · doc1.xml · derivative · entry 2 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,028 Underlying: Common Stock · 32,028 shares Expires 2033-02-17 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve monthly installments of 2,669 shares beginning on March 17, 2023 and continuing every month thereafter until fully vested. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:18 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Tax withholdingCommon Stock | 53,750 | $1.47 | $79,012.50 |
DisclosureSEC source: 0001540354-23-000001 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 460,858 Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 21:23 UTC | Healthcare Triangle, Inc. HCTI · Entity 7909 | GrantStock Option (Right to Buy) · Derivative | 1 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001607062-23-000041 · ownership.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-01-27 Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:18 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 10,490 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001567619-22-019189 · doc1.xml · derivative · entry 2 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,490 Underlying: Common Stock · 10,490 shares Expires 2031-11-04 F2 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F1 · derivative.exercise_date: The option vests and becomes exercisable in eight nearly-equal, quarterly installments beginning on February 4, 2022 and continuing every three months thereafter until fully vested. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:18 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 10,490 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-22-019189 · doc1.xml · derivative · entry 1 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,490 shares Expires 2031-11-04 F2 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F1 · derivative.exercise_date: The option vests and becomes exercisable in eight nearly-equal, quarterly installments beginning on February 4, 2022 and continuing every three months thereafter until fully vested. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 23:26 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001540354-22-000001 · primary_doc.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,608 F1 · shares: Represents a grant of restricted stock units, which vest as to 50% of the shares on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments on the last day of each month over the next 24 months, subject to continued service on such vesting date. Read SEC document |
| November 29, 2021 Filed Dec 3, 2021 14:38 UTC | BIOTRICITY INC. BTCY · Entity 8507 | GrantCommon Stock | 27,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-030377 · ownership.xml · nonDerivative · entry 1 Rosa David A · CIK 0001540354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,174 F1 · shares: Granted in connection with the Reporting Person's service on the Company's board. Such shares were issued pursuant the Company's 2016 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.